News

Latest News:

MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis

POSTED: September 24, 2019

Copenhagen, September 24th, 2019 – MC2 Therapeutics, a late clinical-stage pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that it has submitted a ...

READ FULL ARTICLE >

MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients with Plaque Psoriasis Treated with MC2-01 PADTM Cream

POSTED: August 7, 2019

  • Topline data are expected in Q4 2019

Copenhagen, August 7th, 2019 – MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the ...

READ FULL ARTICLE >

MC2 Therapeutics A/S appoints Samia Kappe as Executive Vice President Sales & Marketing Europe

POSTED: April 4, 2019

Copenhagen, April 4th, 2019 – MC2 Therapeutics A/S, a late clinical-stage company focused on topical therapies for chronic inflammatory conditions, today announced the appointment of Samia Kappe as Executive Vice ...

READ FULL ARTICLE >

MC2 Therapeutics A/S announces first patient dosed in EU Phase 3 trial in psoriasis vulgaris

POSTED: January 6, 2019

  • First patient dosed in Phase 3 trial assessing the safety and efficacy of MC2-01  Cream in EU
  •  Topline results are expected in Q3 2019

Copenhagen, January 6th, 2019 – MC2 Therapeutics A/S, ...

READ FULL ARTICLE >

Upcoming Events:

October 17th - 19th, 2019

MC2 Therapeutics to present at the European Association for Vision and Eye Research (EVER)

READ MORE >

October 17th - 20th, 2019

MC2 Therapeutics as gold level sponsor of the 2019 Fall Clinical Dermatology Conference

READ MORE >

November 20th - 21st, 2019

Jefferies 2019 London Healthcare Conference

READ MORE >

© mc2 therapeutics 2016